![]() ![]() To provide additional clarification on filing requirements Longer sent following the processing of the notifications) Regards to the process change (confirmation emails are no To provide clarification to the existing practices and in Minor updates throughout Sections 6.3-6.8 Updates to the status descriptions and addition ofĭefinition for a Restricted access status ![]() Report drug shortages and discontinuations may apply to To provide clarification to the existing practicesĪ reminder that additional requirements to publically Minor addition in regards to the issuance of multiple DINs Process changes and feedback from the internal and external General updates throughout the document based on the ![]() Instructions regarding notification of discontinuation of sale from the manufacturer.Ĭorrection to list of submission type Section 6.8 Reissuance of a DIN by Health Canada. More information on the requirements for submitting a Notification of discontinuation of sale in Section 6.5 of the guidance. To provide clarification on the concept of availability of a drug on the Canadian market To make it easier to find information relating to DINs by consolidating a number of policies and guidance document into a single document.Īddition of the following wording: "(available for immediate use via hospital and retail pharmacies )"
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |